Benzinga | Jan 25, 2022 05:00AM EST

Stifel Upgrades Blueprint Medicines to Buy, Lowers Price Target to $95

Stifel analyst Bradley Canino upgrades Blueprint Medicines (NASDAQ:BPMC) from Hold to Buy and lowers the price target from $120 to $95.